Literature DB >> 25947001

Association Between Basal Thinning of Interventricular Septum and Adverse Long-Term Clinical Outcomes in Patients With Cardiac Sarcoidosis.

Nobutaka Nagano1, Toshiyuki Nagai, Yasuo Sugano, Yoshiaki Morita, Yasuhide Asaumi, Takeshi Aiba, Hideaki Kanzaki, Kengo Kusano, Teruo Noguchi, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai.   

Abstract

BACKGROUND: Basal thinning of the interventricular septum (IVS) is an important diagnostic feature of cardiac sarcoidosis (CS), but its long-term prognostic significance remains unclear. METHODS AND
RESULTS: We examined 74 consecutive patients who were diagnosed with CS. Basal IVS thickness at a point located 10 mm from the aortic annulus was measured. IVS thickness at the left ventricular minor axis level (IVS) was also measured according to the recommended procedure of the American Society of Echocardiography. Patients were divided into 2 groups based on the presence or absence of basal IVS thinning, which was defined as basal IVS ≤4 mm and/or basal IVS/IVS ratio ≤0.6. Basal IVS thinning was observed in 21 patients and was associated with greater long-term adverse events during follow-up (5.1±2.5 years), although the baseline characteristics were comparable between groups (overall, P<0.01; all-cause death, P=0.53; symptomatic arrhythmias, P<0.01; heart failure admission, P=0.027). Multivariate analysis showed basal IVS thinning was an independent determinant of long-term adverse events (hazard ratio 2.86, 95% confidence interval 1.31-6.14) even after adjustment for existing prognostic variables.
CONCLUSIONS: The presence of basal IVS thinning at the time of CS diagnosis was associated with poor long-term clinical outcomes, suggesting its prognostic significance in patients with CS.

Entities:  

Mesh:

Year:  2015        PMID: 25947001     DOI: 10.1253/circj.CJ-14-1217

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

Review 1.  Viewpoints in the diagnosis and treatment of cardiac sarcoidosis: Proposed modification of current guidelines.

Authors:  Dae-Won Sohn; Jun-Bean Park; Seung-Pyo Lee; Hyung-Kwan Kim; Yong-Jin Kim
Journal:  Clin Cardiol       Date:  2018-10-17       Impact factor: 2.882

2.  Cardiac sarcoidosis resembling panic disorder: a case report.

Authors:  Keita Tokumitsu; Jun Demachi; Yukichi Yamanoi; Shigeto Oyama; Junko Takeuchi; Koji Yachimori; Norio Yasui-Furukori
Journal:  BMC Psychiatry       Date:  2017-01-13       Impact factor: 3.630

3.  Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25-Year Nationwide Cohorts.

Authors:  Hanna-Kaisa Nordenswan; Jukka Lehtonen; Kaj Ekström; Anne Räisänen-Sokolowski; Mikko I Mäyränpää; Tapani Vihinen; Heikki Miettinen; Kari Kaikkonen; Petri Haataja; Tuomas Kerola; Tuomas T Rissanen; Jorma Kokkonen; Aleksi Alatalo; Päivi Pietilä-Effati; Seppo Utriainen; Markku Kupari
Journal:  J Am Heart Assoc       Date:  2021-03-04       Impact factor: 5.501

4.  Utility of Updated Japanese Circulation Society Guidelines to Diagnose Isolated Cardiac Sarcoidosis.

Authors:  Kimi Sato; Naoto Kawamatsu; Masayoshi Yamamoto; Tomoko Machino-Ohtsuka; Tomoko Ishizu; Masaki Ieda
Journal:  J Am Heart Assoc       Date:  2022-06-29       Impact factor: 6.106

5.  Magnetic Resonance Imaging as a Predictor of Survival Free of Life-Threatening Arrhythmias and Transplantation in Cardiac Sarcoidosis.

Authors:  Kaj Ekström; Jukka Lehtonen; Helena Hänninen; Riina Kandolin; Sari Kivistö; Markku Kupari
Journal:  J Am Heart Assoc       Date:  2016-05-02       Impact factor: 5.501

6.  Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis.

Authors:  Cristina Di Stefano; Giulia Bruno; Maria C Arciniegas Calle; Gayatri A Acharya; Lynn M Fussner; Patompong Ungprasert; Leslie T Cooper; Lori A Blauwet; Jay H Ryu; Patricia A Pellikka; Eva M Carmona Porquera; Hector R Villarraga
Journal:  BMC Cardiovasc Disord       Date:  2020-01-20       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.